AMI Cardiogenic Shock
Clinical Evidence
AMI Cardiogenic Shock

Clinical Evidence

Key Findings from the National Cardiogenic Shock Initiative Study 1,2,3

  • Identify and support cardiogenic shock early
  • Aggressive down titration inotropes
  • Identify inadequate left ventricular (LV) support and escalate, if CPO <0.6
  • Identify right ventricular (RV) dysfunction early and support
  • Systematically use right heart catheter (RHC) to guide therapy
Graphic displaying the pathway to class 1 recommendation of Impella use in cardiogenic shock

Impella® Clinical Evidence Pathway to Class I Recommendation

Impella clinical evidence has established safety and effectiveness and validated best practices.

Graphic of clinical evidence supporting improved AMI cardiogenic shock outcomes when unloading pre-PCI

Ongoing and Upcoming Clinical Trials

RECOVER IV Randomized Controlled Trial

Upcoming trial to assess whether Impella pre-PCI is superior to PCI without Impella in patients with AMI cardiogenic shock.

NCSI Study

Ongoing trial seeking to improve mortality in patients with AMI cardiogenic shock using the NCSI algorithm.

DanGer Shock Randomized Controlled Trial

Ongoing trial assessing primary outcome of death from all causes at six months with Impella CP® compared to standard of care.

The Procedure

Learn more about femoral access explant techniques and other best practices.

References

  1. Tehrani, et al. (2019). JACC, 73, 1659-1669.
  2. Basir, M.B., et al. (2019). Catheter Cardiovasc Interv, 93(7), 1173-1183.
  3. O’Neill, W.W., (2020). TCT Connect 2020

NPS-1187

The Protected PCI community
is now on HeartRecovery.com

Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
Explore Now